AI assistant
FATE THERAPEUTICS INC — Director's Dealing 2022
Mar 11, 2022
34091_dirs_2022-03-11_e56cfad1-91b7-4c04-99fa-88f8b111addd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2022-03-10
Reporting Person: MENDLEIN JOHN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-10 | Common Stock | M | 31562 | $1.63 | Acquired | 191017 | Direct |
| 2022-03-10 | Common Stock | S | 19493 | $34.73 | Disposed | 171524 | Direct |
| 2022-03-10 | Common Stock | S | 12069 | $35.48 | Disposed | 159455 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-10 | Stock Option (Right to Buy) | $1.63 | M | 31562 | Disposed | 2022-03-12 | Common Stock (31562) | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.
F2: Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
F3: Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
F4: This option is fully vested.